A PHASE II TRIAL OF GEMCITABINE, IFOSFAMIDE, DEXAMATHASONE, AND OXALIPLATIN (GIDOX) FOR PATIENTS WITH REFRACTORY OR RELAPSED NON-HODGKIN'S LYMPHOMA

被引：0
|
作者：
Park, B. B. [1 ]
Kim, W. S. [2 ]
Eom, H. S. [3 ]
Kim, J. S. [4 ]
Oh, S. J. [5 ]
Hwang, I. G. [6 ]
Suh, C. [7 ]
机构：
[1] Hanyang Univ, Coll Med, Seoul 133791, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[3] Natl Canc Ctr, Res Inst & Hosp, Goyang, South Korea
[4] Yonsei Univ, Coll Med, Seoul, South Korea
[5] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Seoul, South Korea
[6] Chung Ang Univ, Sch Med, Seoul 156756, South Korea
[7] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1701
引用
收藏
页码：652 / 652
页数：1
相关论文
共 50 条
  • [1] A phase II trial of gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for patients with refractory or relapsed non-Hodgkin's lymphoma
    Park, B.
    Kim, W.
    Eom, H.
    Kim, J.
    Oh, S.
    Suh, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Phase II study of ifosfamide, etoposide, and oxaliplatin (IFETOx) chemotherapy for relapsed or refractory non-Hodgkin’s lymphoma
    Seon-Kyeong Kim
    Moo-Kon Song
    Joo Seop Chung
    Ho-Jin Shin
    International Journal of Hematology, 2013, 98 : 543 - 548
  • [3] Phase II study of ifosfamide, etoposide, and oxaliplatin (IFETOx) chemotherapy for relapsed or refractory non-Hodgkin's lymphoma
    Kim, Seon-Kyeong
    Song, Moo-Kon
    Chung, Joo Seop
    Shin, Ho-Jin
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 98 (05) : 543 - 548
  • [4] Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial
    Ding, Kaiyang
    Liu, Hailing
    Ma, Jie
    Yang, Haiyan
    Cao, Lei
    Wang, Huihan
    Peng, Hongling
    Shi, Wei
    Zhao, Xiaoli
    Wu, Wei
    Zhu, Huayuan
    Li, Jianyong
    Fan, Lei
    HAEMATOLOGICA, 2023, 108 (08) : 2146 - 2154
  • [5] A Phase II Study of Gemcitabine, Rituximab, and Oxaliplatin In Combination for Relapsed/Refractory Non-Hodgkin's Lymphomas
    Cultrera, Jennifer L.
    Liu, Jijun
    Liboy, Idalia
    Bello, Celeste M.
    Sokol, Lubomir
    Sotomayor, Eduardo M.
    Santana, Enrique
    Cabanillas, Fernando
    BLOOD, 2010, 116 (21) : 1186 - 1186
  • [6] Phase II study of oxaliplatin in patients with relapsed or refractory non-Hodgkin's lymphoma: Final results.
    Oki, Y
    McLauhlin, P
    Pro, B
    Hagemeister, FH
    Bleyer, A
    Loyer, E
    Younes, A
    BLOOD, 2004, 104 (11) : 684A - 684A
  • [7] Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial
    Liu, Yanfei
    Ping, Lingyan
    Song, Yuqin
    Tang, Yongjing
    Zheng, Wen
    Liu, Weiping
    Ying, Zhitao
    Zhang, Chen
    Wu, Meng
    Feng, Feier
    Lin, Ningjing
    Tu, Meifeng
    Zhu, Jun
    Xie, Yan
    BMC MEDICINE, 2024, 22 (01)
  • [8] Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial
    Yanfei Liu
    Lingyan Ping
    Yuqin Song
    Yongjing Tang
    Wen Zheng
    Weiping Liu
    Zhitao Ying
    Chen Zhang
    Meng Wu
    Feier Feng
    Ningjing Lin
    Meifeng Tu
    Jun Zhu
    Yan Xie
    BMC Medicine, 22
  • [9] Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial
    Park, Byeong-Bae
    Kim, Won Seog
    Eom, Hyeon Seok
    Kim, Jin Seok
    Lee, Young Yiul
    Oh, Suk Joong
    Lee, Dae Ho
    Suh, Cheolwon
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (01) : 154 - 160
  • [10] Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin’s lymphoma: a consortium for improving survival of lymphoma (CISL) trial
    Byeong-Bae Park
    Won Seog Kim
    Hyeon Seok Eom
    Jin Seok Kim
    Young Yiul Lee
    Suk Joong Oh
    Dae Ho Lee
    Cheolwon Suh
    Investigational New Drugs, 2011, 29 : 154 - 160
12345